All In Biotech

Drug Trial Radar · NCT04498117

Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery

A Multicenter Phase 3, Double-Blind, Placebo-Controlled Study Comparing Chemo-Immunotherapy (Paclitaxel-Carboplatin- Oregovomab) vs Chemotherapy (Paclitaxel-Carboplatin- Placebo) in Patients With Advanced Epithelial Ovarian, Fallopian Tube or Peritoneal Carcinoma

Last checked: Nov 19, 2026Latest source record: Apr 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 615 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

615

Actual

Start

Aug 25, 2020

Primary completion

Dec 26, 2026

Study completion Aug 26, 2028

Sponsor

Lead sponsor
CanariaBio Inc.Industry
Sponsor type
Industry
Collaborators
Gynecologic Oncology Group; IQVIA Pty Ltd
First posted
Aug 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Study to compare the safety and efficacy of oregovomab versus placebo, administered in combination with specific cycles of a standard six-cycle chemotherapy regimen (paclitaxel and carboplatin), for the treatment of subjects with newly diagnosed advanced ovarian cancer who have undergone optimal debulking.

Conditions

  • Carcinoma, Ovarian Epithelial
  • Ovarian Neoplasms
  • Ovarian Cancer
  • Ovarian Serous Adenocarcinoma
  • Fallopian Tube Neoplasms
  • Fallopian Tube Adenocarcinoma
  • Fallopian Tube Serous Adenocarcinoma
  • Peritoneal Cancer
  • Peritoneal Carcinoma
  • Peritoneal Neoplasms

Interventions

  • OregovomabBiological

    2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

  • PaclitaxelDrug

    175 mg/m\^2, every 3 weeks

  • CarboplatinDrug

    AUC 6 IV Day 1 x 6 cycles (every 21 days)

  • PlaceboBiological

    2 mg, dissolved in 2 mL of 0.9% Sodium Chloride Injection USP, then added to 50 mL of Sodium Chloride Injection USP infused over 20 ± 5 minutes

  • CarboplatinDrug

    AUC 5-6 IV Day 1 x 6 cycles (every 21 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Investigator Assessed Progression Free SurvivalTime frame: Date of randomization until date of first documented disease progression or date of death from any cause, whichever comes first, at up to approximately 6 years.

Locations

148 sites in 14 countries. Site status is shown where the registry gives one.

  • Honor Health

    Phoenix, Arizona

  • The University of Arizona Cancer Center

    Tucson, Arizona

  • John Muir Health Clinical Research Center

    Concord, California

  • Kaiser Permanente Southern California

    Irvine, California

  • Moores UC San Diego Cancer Center

    La Jolla, California

  • Kaiser Permanente Los Angeles Medical Center

    Los Angeles, California

  • Epic Care

    Pleasant Hill, California

  • Kaiser Permanente Riverside Medical Center

    Riverside, California

  • University of California, Davis Comprehensive Cancer Center

    Sacramento, California

  • Contra Costa Oncology

    Walnut Creek, California

  • John Muir Health Gynecologic Cancer Services

    Walnut Creek, California

  • University of Colorado Health

    Aurora, Colorado

  • University of Connecticut Health Center

    Farmington, Connecticut

  • Smilow Cancer Hospital

    New Haven, Connecticut

  • Yale University School of Medicine

    New Haven, Connecticut

  • AdventHealth Orlando

    Orlando, Florida

  • Women's Cancer Florida/Women's Cancer Associates

    St. Petersburg, Florida

  • Lewis Cancer & Research Pavilion at St. Joseph's Candler

    Savannah, Georgia

  • The Queens Medical Center

    Honolulu, Hawaii

  • Kapiolani Medical Center for Women and Children/University of Hawaii

    Honolulu, Hawaii

  • Parkview Research Center

    Fort Wayne, Indiana

  • Women's Cancer Care/Mary Bird Perkins Cancer Center

    Covington, Louisiana

  • Tufts Medical Center

    Boston, Massachusetts

  • Lahey Hospital and Medical Center

    Burlington, Massachusetts

  • MetroWest Medical Center

    Farmington, Massachusetts

  • Lowell General Hospital

    Lowell, Massachusetts

  • Tufts Medical Center Cancer Center in Stoneham

    Stoneham, Massachusetts

  • UMass Memorial Medical Center

    Worcester, Massachusetts

  • St. Joseph Mercy Hospital

    Ann Arbor, Michigan

  • Sparrow Hospital

    Lansing, Michigan

  • Minnesota Oncology Hematology - Mercy Hospital

    Coon Rapids, Minnesota

  • Minnesota Oncology Hematology

    Edina, Minnesota

  • University of Minnesota Health - Maple Grove Clinic

    Maple Grove, Minnesota

  • Minnesota Oncology Hematology

    Minneapolis, Minnesota

  • Metro Minnesota Community Oncology Research Consortium

    Saint Louis Park, Minnesota

  • Park Nicollet Frauenshuh Cancer Center

    Saint Louis Park, Minnesota

  • Minnesota Oncology Hematology

    Saint Paul, Minnesota

  • Nebraska Methodist Hospital

    Omaha, Nebraska

  • Portsmouth Regional Hospital

    Portsmouth, New Hampshire

  • Rutgers Cancer Institute of New Jersey

    New Brunswick, New Jersey

Showing 40 of 148 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.